P75 Tumor Necrosis Factor-Receptor Shedding Occurs as a Protective Host Response during African Trypanosomiasis

Journal of Infectious Diseases

Volumn 189, Issue 3, 2004, Pages 527-539

  Magez, Stefan ^a,d,e   Truyens, Carine ^b   Merimi, Makram ^a   Radwanska, Magdalena ^c,d   Stijlemans, Benoît ^a   Brouckaert, Peter ^a   Brombacher, Frank ^d   Pays, Etienne ^c   De Baetselier, Patrick ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; PROTEIN P75; TUMOR NECROSIS FACTOR;

AFRICAN TRYPANOSOMIASIS; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL INFECTION; FEMALE; LOCOMOTION; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECIES COMPARISON; SURVIVAL RATE; TRYPANOSOMA BRUCEI; VIRUS INHIBITION; VIRUS SHEDDING; VIRUS SURVIVAL; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD; DISEASE MODELS, ANIMAL; FEMALE; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; ORGAN SIZE; PARASITEMIA; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TIME FACTORS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 1142273119     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381151     Document Type: Article

References (51)

1. World Health Organization. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1998; 881:I-1V, 1-114.
2. Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN. Measuring the cost of African trypanosomiasis: the potential benefits of control and returns to research. Agric Syst 1999; 59:79-98.
3. Van de Bossche P. Some general aspects of the distribution and epidemiology of bovine trypanosomiasis in southern Africa. Int J Parasitol 2001; 31:592-8.
4. Vanhamme L, Pays E, McCulloch R, Barry JD. An update on antigenic variation in African trypanosomes. Trends Parasitol 2001; 17:338-43.
5. Turner CMR. Antigenic variation in Trypanosoma brucei infections: an holistic view. J Cell Sci 1999; 112:3187-92.
6. Okomo-Assoumou MC, Daulouede S, Lemesre JL, N'Zila-Mouanda A, Vincendeau P. Correlation of high serum levels of tumor necrosis factor-α with disease severity in human African trypanosomiasis. Am J Trop Med Hyg 1995; 53:539-43.
7. Sileghem M, Flynn JN, Logan-Henfrey L, Ellis J. Tumour necrosis factor production by monocytes from cattle infected with Trypanosoma (Duttonella) vivax and Trypanosoma (Nannomonas) congolense: possible association with severity of anemia associated with the disease. Parasite Immunol 1994; 16:51-4.
8. Hunter CA, Gow JW, Kennedy PG, Jennings FW, Murray M. Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice. Infect Immun 1991; 59:4636-40.
9. Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA, De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol 1998; 160:1949-56.
10. Tachado SD, Schofield L. Glycosylphosphatidylinositol toxin of Trypanosoma brucei regulates IL-1α and TNF-α expression in macrophages by protein tyrosine kinase-mediated signal transduction. Biochem Biophys Res Commun 1994; 205:984-91.
11. Magez S, Radwanska M, Beschin A, Sekikawa K, De Baetselier P. TNF-α is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 1999; 67:3128-32.
12. Lejon V, Lardon J, Kenis G, et al. Interleukin (IL)-6, IL-8, and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg 2002; 96:329-33.
13. MacLean L, Odiit M, Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 2001; 184:1086-90.
14. Aggerwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996; 7:93-124.
15. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10:411-52.
16. Bemelmans MH, Gouma DJ, Burrman WA. LPS-induced sTNF-receptor release in vivo in a murine model: investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and interferon-γ. J Immunol 1993; 151:5554-62.
17. Himmler A, Maurer-Fogy I, Kronke M, et al. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol 1990; 9:705-15.
18. Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs): the cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both cell surface and a soluble form of the receptor. EMBO J 1990; 9:3269-78.
19. Fernandez-Botran R, Chilton PM, Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv Immunol 1996; 63:269-336.
20. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-61.
21. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumour necrosis factor (TNF)-binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993; 4:169-80.
22. Truyens C, Torrico F, Lucas R, De Baetselier P, Burrman WA, Carlier Y. The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun 1999; 67:5579-86.
23. Hertz CJ, Filutowicz H, Mansfield JM. Resistance to the African trypanosomes is IFN-γ dependent. J Immunol 1998; 161:6775-83.
24. Namangala B, Noel W, De Baetselier P, Brys L, Beschin A. Relative contribution of interferon-γ and interleukin-10 to resistance to murine African trypanosomiasis. J Infect Dis 2001; 183:1794-800.
25. Schopf LR, Filutowicz H, Bi XJ, Mansfield JM. Interleukin-4-dependent immunoglobulin G1 isotype switch in the presence of a polarized antigen-specific Th1-cell response to the trypanosome variant surface glycoprotein. Infect Immun 1998; 66:451-61.
26. Kaushik RS, Uzonna JE, Zhang Y, Gordon JR, Tabel H. Innate resistance to experimental African trypanosomiasis: differences in cytokine (TNF-α, IL-6, IL-10, and IL-12) production by bone marrow-derived macrophages from resistant and susceptible mice. Cytokine 2000; 12:1024-34.
27. Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364:798-802.
28. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372:560-3.
29. Anosa VO, Kaneko JJ. Pathogensis of Trypanosoma brucei infections in deer mice (Peromyscus maniculatus): ultrastuctural pathology of the spleen, liver, heart, and kidney. Vet Pathol 1984; 21:229-37.
30. Shi M, Pan W, Tabel H. Experimental African trypanosomiasis: IFN-gamma mediates early mortality. Eur J Immunol 2003; 33:108-18.
31. Pentreath VW, Alafiatayo RA, Crawley B, Doua F, Oppenheim BA. Endotoxins in the blood and cerebrospinal fluid of patients with African sleeping sickness. Parasitology 1996; 112:67-73.
32. Alafiatayo RA, Crawley B, Oppenheim BA, Pentreath VW. Endotoxins and the pathogenesis of Trypanosoma brucei brucei infection in mice. Parasitology 1993; 107:49-53.
33. Schmidt H, Bafort JM. African trypanosomiasis: haematogenic brain parasitism early in experimental infection through bypassing the blood-brain barrier, with considerations on brain trypanosomiasis in man. Parasitol Res 1987; 73:15-21.
34. Sileghem M, Naessens J. Are CD8 T cells involved in control of African trypanosomiasis in a natural host environment? Eur J Immunol 1995; 25:1965-71.
35. Mulenga C, Mhlanga JD, Kristensson K, Robertson B. Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. Neuropathol Appl Neurobiol 2001; 27:77-85.
36. Lein E, Laibakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 1995; 25:2714-7.
37. Steinshamn S, Bemelmans MH, van Tits LJ, Bergh K, Buurman WA, Waage A. TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J Immunol 1996; 157:2155-9.
38. Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol 1997; 158:3869-73.
39. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175:323-9.
40. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282:1281-4.
41. Coyne CP, Willeto C, Fenwick BW. A mechanism of TNFR type II (75kDa) "shedding" in macrophages. Shock 1999; 11:19-28.
42. Joyce DA, Steer JH. Tumor necrosis factor alpha and interleukin-1 stimulate late shedding of p75 TNF receptor but not p55 TNF receptors from human monocytes. J Interferon Cytokine Res 1995; 15:947-54.
43. Joyce DA, Gibbons PD, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24:2699-705.
44. Lucas R, Magez S, De Leys R, et al. Mapping the lectin-like activity of tumor necrosis factor. Science 1994; 263:814-7.
45. Kitani H, Black SJ, Nakamura Y, et al. Recombinant tumor necrosis factor alpha does not inhibit the growth of African trypanosomes in axenic cultures. Infect Immun 2002; 70:2210-4.
46. Tizard IR, Holmes WL, Nielsen K. Mechanisms of the anemia in trypanosomiasis: studies on the role of the hemolytic fatty acids derived from Trypanosoma congolense. Tropenmed Parasitol 1978; 29:108-14.
47. Rifkin MR, Landsberger FR. Trypanosome variant surface glycoprotein transfer to target membranes: a model for the pathogenesis of trypanosomiasis. Proc Natl Acad Sci USA 1990; 87:801-5.
48. Witola WH, Lovelace CE. Demonstration of erythrophagocytosis in Trypanosoma congolense-infected goats. Vet Parasitol 2001; 96:115-26.
49. Taiwo VO, Anosa VO. In vitro erythrophagocytosis by cultured macrophages stimulated with extraneous substances and those isolated from the blood, spleen and bone marrow of Boran and N'Dama cattle infected with Trypanosoma congolense and Trypanosoma vivax. Onderstepoort J Vet Res 2000; 67:273-87.
50. Branch DR, Guilbert LJ. Autocrine regulation of macrophage proliferation by tumor necrosis factor-alpha. Exp Hematol 1996; 24:675-81.
51. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992; 22:1447-54.